SHIM
NAMS icon

Stone House Investment Management’s NewAmsterdam Pharma NAMS Stock Holding History

Stone House Investment Management’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$10.4K Hold
325
– – ﹤0.01% 345
2025
Q4 		$11.4K Hold
325
– – ﹤0.01% 307
2025
Q3 		$9.24K Hold
325
– – ﹤0.01% 298
2025
Q2 		$5.89K Hold
325
– – ﹤0.01% 304
2025
Q1 		$6.65K Buy
+325
New +$7.22K ﹤0.01% 287
2024
Q4 		– Sell
-325
Closed -$5.39K – 246
2024
Q3 		$5.39K Hold
325
– – ﹤0.01% 267
2024
Q2 		$6.24K Hold
325
– – ﹤0.01% 260
2024
Q1 		$7.69K Buy
+325
New +$6.6K ﹤0.01% 251

Other funds holding NAMS

FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
DFO
Duquesne Family Office New York $3.38B AUM 61.92% 1-Year Est. Return

Stone House Investment Management's NAMS Position: Q1 2026 in Review

Stone House Investment Management held its NewAmsterdam Pharma (NAMS) position steady in Q1 2026 at 325 shares worth $10.4K. The position accounts for ﹤0.01% of the portfolio, ranked #345.

Stone House Investment Management first reported a position in NAMS in Q1 2024 and has held it in 8 quarters since. The position peaked at $11.4K in Q4 2025. 170 funds tracked by Wall St. Rank hold NAMS as of Q1 2026.

  • Stone House Investment Management held 325 shares of NewAmsterdam Pharma worth $10.4K as of Q1 2026.
  • Stone House Investment Management left its NewAmsterdam Pharma share count unchanged in Q1 2026.
  • NewAmsterdam Pharma made up ﹤0.01% of Stone House Investment Management's portfolio in Q1 2026, its #345 holding.
  • Stone House Investment Management first reported a position in NewAmsterdam Pharma in Q1 2024 and has held it in 8 quarters since.
  • Stone House Investment Management's NewAmsterdam Pharma position peaked at $11.4K in Q4 2025.
  • 170 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q1 2026.

Based on Stone House Investment Management's 13F filing for Q1 2026, filed 22 Apr 2026.